Epidemiology and risk factors for drug allergy

British Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2011, Pages 684-700

  Thong, Bernard Y H ^a   Tan, Teck Choon ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Adverse drug reaction; Anaphylaxis; Mortality; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CEPHALOSPORIN DERIVATIVE; CONTRAST MEDIUM; COTRIMOXAZOLE; DIPYRONE; FUROSEMIDE; GENTAMICIN; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PREDNISOLONE; UNINDEXED DRUG;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD TOXICITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EMERGENCY WARD; ERYTHEMA MULTIFORME; ERYTHRODERMA; EVIDENCE BASED MEDICINE; EXFOLIATIVE DERMATITIS; FEVER; GENETIC ASSOCIATION; GENETIC SCREENING; HLA SYSTEM; HUMAN; INCIDENCE; LIVER TOXICITY; MACULOPAPULAR RASH; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; RISK FACTOR; SEVERE CUTANEOUS ADVERSE REACTION; SKIN ALLERGY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AMBULATORY CARE FACILITIES; CHILD; DRUG HYPERSENSITIVITY; EMERGENCY SERVICE, HOSPITAL; GENETIC PREDISPOSITION TO DISEASE; HOSPITALIZATION; HUMANS; RISK FACTORS;

EID: 79953857398     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03774.x     Document Type: Article

References (130)

1. World Health Organization. International drug monitoring: the role of national centres. World Health Organ Tech Rep Ser 1972; 498: 1-25.
2. Rawlins MD, Thompson JV. Pathogenesis of adverse drug reactions. In: Textbook of Adverse Drug Reactions, ed. Davies DM. Oxford: Oxford University Press, 1977; 10.
3. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13: 306-14.
4. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
5. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
6. Guillaume JC, Rojeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987; 123: 1166-70.
7. Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J, Schöpf E. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11.
8. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55: 9-16.
9. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
10. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol Int 2006; 55: 1-8.
11. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-9.
12. Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9: 322-8.
13. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006; 117: 391-7.
14. Lieberman P. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 316-20.
15. Demoly P, Viola M, Gomes ER, Romano A. Epidemiology and causes of drug hypersensitivity. In: Drug Hypersensitivity, ed. Pichler WJ. Basel: Karger, 2007; 2-17.
16. Mockenhaupt M. Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Drug Hypersensitivity, ed. Pichler WJ. Basel: Karger, 2007; 18-31.
17. Bousquet PJ, Demoly P, Romano A, Aberer W, Bircher A, Blanca M, Brockow K, Pichler W, Torres MJ, Terreehorst I, Arnoux B, Atanaskovic-Markovic M, Barbaud A, Bijl A, Bonadonna P, Burney PG, Caimmi S, Canonica GW, Cernadas J, Dahlen B, Daures JP, Fernandez J, Gomes E, Gueant JL, Kowalski ML, Kvedariene V, Mertes PM, Martins P, Nizankowska-Mogilnicka E, Papadopoulos N, Ponvert C, Pirmohamed M, Ring J, Salapatas M, Sanz ML, Szczeklik A, Van Ganse E, De Weck AL, Zuberbier T, Merk HF, Sachs B, Sidoroff A, Global Allergy, Asthma European Network (GALEN) and Drug Allergy and Hypersensitivity Database (DAHD) and the European Network for Drug Allergy (ENDA). Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy 2009; 64: 194-203.
18. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy 1999; 54: 999-1003.
19. Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, Aberer W, Brockow K, Pichler WJ, Demoly P, ENDA, EAACI Interest Group on Drug Hypersensitivity. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58: 961-72.
20. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, Pichler WJ, Demoly P, ENDA, EAACI. Diagnosis of non-immediate reactions to beta-lactam antibiotics. Allergy 2004; 59: 1153-60.
21. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P, European Network for Drug Allergy (ENDA), EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-63.
22. Allain H, Chevrant-Breton J, Beneton C, Bousser AM, Bentue-Ferrer D, Mazeas D, Van der Driessche J. Undesirable dermatologic results of drugs. Results of a drug monitoring survey (French). Ann Med Interne (Paris) 1983; 134: 530-6.
23. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Programme on 15438 consecutive patients, 1975 to 1982. JAMA 1986; 256: 3358 - 63.
24. Classen DC, Pestonik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospitalized patients. JAMA 1991; 266: 2847-51.
25. Rademaker M, Oakley A, Dufill MB. Cutaneous adverse drug reactions in a hospital setting. N Z Med J 1995; 108: 165-6.
26. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-93.
27. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents - a 6 year series from Chandigarh, India. J Postgrad Med 2001; 47: 95-9.
28. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003; 90: 342-47.
29. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-22.
30. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37: 899-902.
31. Park CS, Kim TB, Kim SL, Kim JY, Yang KA, Bae YJ, Cho YS, Moon HB. The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. Pharmacoepidemiol Drug Saf 2008; 17: 919-25.
32. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch Dis Child 2009; 94: 724-8.
33. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/outpatients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83.
34. Rebelo Gomes E, Fonseca J, Araujo L, Demoly P. Drug allergy claims in children: from self-reporting to confirmed diagnosis. Clin Exp Allergy 2008; 38: 191-8.
35. Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. Pediatrics 2006; 118: 555-62.
36. Gamboa PM. The epidemiology of drug allergy-related consultations in Spanish Allergology Services: Alergológica-2005. J Investig Allergol Clin Immunol 2009; 19: (Suppl. 2): 45-50.
37. Ibáñez MD, Garde JM. Allergy in patients under fourteen years of age in Alergológica 2005. J Investig Allergol Clin Immunol 2009; 19: (Suppl. 2): 61-8.
38. England RW, Ho TC, Napoli DC, Quinn JM. Inpatient consultation of allergy/immunology in a tertiary care setting. Ann Allergy Asthma Immunol 2003; 90: 393-7.
39. Dietrich JJ, Quinn JM, England RW. Reasons for outpatient consultation in allergy/immunology. Allergy Asthma Proc 2009; 30: 69-74.
40. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-66.
41. Cohen AL, Budnitz DS, Weidenbach KN, Jernigan DB, Schroeder TJ, Shehab N, Pollock DA. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. J Pediatr 2008; 152: 416-21.
42. Dantonio C, Galimberti M, Barbone B, Calamari M, Airoldi G, Campanini M, Di Pietrantonj C, Avanzi GC. Suspected acute allergic reactions: analysis of admissions to the Emergency Department of the AOU Maggiore della Carit Hospital in Novara from 2003 to 2007. Eur Ann Allergy Clin Immunol 2008; 40: 122-9.
43. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008; 64: 743-52.
44. Salvo F, Polimeni G, Cutroneo PM, Leone R, Confortic A, Moretti U, Motola D, Tuccori M, Caputi AP. Allergic reactions to oral drugs: a case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacol Res 2008; 58: 202-7.
45. Fuzier R, Lapeyre-Mestre M, Mertes PM, Nicolas JF, Benoit Y, Didier A, Albert N, Montastruc JL. French Association of Regional Pharmacovigilance Centers. Immediate- and delayed-type allergic reactions to amide local anesthetics: clinical features and skin testing. Pharmacoepidemiol Drug Saf 2009; 18: 595-601.
46. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110: 341-8.
47. Yocum MW, Khan DA. Assessment of patients who have experienced anaphylaxis: a 3-year survey. Mayo Clin Proc 1994; 69: 16-23.
48. Kemp SF, Lockey RF, Wolf BL, Lieberman P. Anaphylaxis: a review of 266 cases. Arch Intern Med 1995; 155: 1749-54.
49. Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy 1996; 26: 1364-70.
50. The International Collaborative Study of Severe Anaphylaxis. An epidemiologic study of severe anaphylactic and anaphylactoid reactions among hospital patients: methods and overall risks. Epidemiology 1998; 9: 141-6.
51. Novembre E, Cianferoni A, Bernardini R, Mugnaini L, Caffarelli C, Cavagni G, Giovane A, Vierucci A. Anaphylaxis in children: clinical and allergologic features. Pediatrics 1998; 101: E8.
52. Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53: 273-6.
53. Pastorello EA, Rivolta F, Bianchi M, Mauro M, Pravettoni V. Incidence of anaphylaxis in the emergency department of a general hospital in Milan. J Chromatogr B Biomed Sci Appl 2001; 756: 11-7.
54. Cianferoni A, Novembre E, Mugnaini L, Lombardi E, Bernardini R, Pucci N, Vierucci A. Clinical features of acute anaphylaxis in patients admitted to a university hospital: an 11-year retrospective review (1985-1996). Ann Allergy Asthma Immunol 2001; 87: 27-32.
55. Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108: 861-6.
56. Helbling A, Hurni T, Mueller UR, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940, 000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004; 34: 285-90.
57. Peng MM, Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch Intern Med 2004; 164: 317-9.
58. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS. Vaccine Safety Datalink Team. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol 2004; 113: 536-42.
59. Cianferoni A, Novembre E, Pucci N, Lombardi E, Bernardini R, Vierucci A. Anaphylaxis: a 7-year follow-up survey of 46 children. Ann Allergy Asthma Immunol 2004; 92: 464-8.
60. Thong BY, Cheng YK, Leong KP, Tang CY, Chng HH. Anaphylaxis in adults referred to a clinical immunology/allergy centre in Singapore. Singapore Med J 2005; 46: 529-34.
61. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol 2006; 97: 39-43.
62. Braganza SC, Acworth JP, Mckinnon DR, Peake JE, Brown AF. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child 2006; 91: 159-63.
63. Low I, Stables S. Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology 2006; 38: 328-32.
64. Jirapongsananuruk O, Bunsawansong W, Piyaphanee N, Visitsunthorn N, Thongngarm T, Vichyanond P. Features of patients with anaphylaxis admitted to a university hospital. Ann Allergy Asthma Immunol 2007; 98: 157-62.
65. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, Kim SH, Kwon HS, Park CH, Park HW, Kim SS, Cho SH, Min KU, Kim YY, Chang YS. Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol 2008; 100: 31-6.
66. Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL, Weaver A, Bellolio MF, Bergstralh EJ, Stead LG, Li JT. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008; 122: 1161-5.
67. de Silva IL, Mehr SS, Tey D, Tang ML. Paediatric anaphylaxis: a 5 year retrospective review. Allergy 2008; 63: 1071-6.
68. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123: 434-42.
69. Tang ML, Osborne N, Allen K. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2009; 9: 351-6.
70. Idsoe O, Guthe T, Willcox RR, DeWeck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968; 38: 159-88.
71. Valentine M, Frank M, Friedland L. Allergic emergencies. In: Asthma and Other Allergic Diseases, NIAID Task Force Report. ed. Drause RM. Bethesda, MD: National Institutes of Health, 1979; 467-507.
72. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115: (Suppl 2): S483-523.
73. Fisher MM, Baldo BA. The incidence and clinical features of anaphylactic reactions during anesthesia in Australia. Ann Fr Anesth Reanim 1993; 12: 97-104.
74. Mertes PM, Laxenaire MC, GERAP. Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002). Ann Fr Anesth Reanim 2004; 23: 1133-43.
75. Thienthong S, Hintong T, Pulnitiporn A. The Thai Anesthesia Incidents Study (THAI Study) of perioperative allergic reactions. J Med Assoc Thai 2005; 88: (Suppl 7): S128-33.
76. Watkins J. Adverse anaesthetic reactions: an update from a proposed national reporting and advisory service. Anaesthesia 1985; 40: 797-800.
77. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology 2005; 102: 897-903.
78. Mertes PM, Lambert M, Guéant-Rodriguez RM, Aimone-Gastin I, Mouton-Faivre C, Moneret-Vautrin DA, Guéant JL, Malinovsky JM, Demoly P. Perioperative anaphylaxis. Immunol Allergy Clin North Am 2009; 29: 429-51.
79. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-7.
80. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1103-4.
81. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraft R, Kapp JF. Toxic epidermal necrolysis and Stevens Johnson Syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-42.
82. Roujeau JC, Guillaume JC, Fabre JP, Penso Dominique P, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell Syndrome). Arch Dermatol 1990; 126: 37-42.
83. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D etal. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991; 127: 831-8.
84. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993; 32: 428-31.
85. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Neil Shear N, Schöpf E, Kaufman DW. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
86. Rzany B, Mockenhaupt M, Baur S, Schröder W, Stocker U, Mueller J, Holländer N, Bruppacher R, Schöpf E. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-73.
87. Kamaliah MD, Zaimal D, Mokhtar N, Nazmi N. Erythema multiforme, Steven Johnson Syndrome and toxic epidermal necrolysis in North East Malaysia. Int J Dermatol 1998; 37: 520-3.
88. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens Johnson Syndrome and toxic epidermal necrolysis. Australas J Dermatol 1999; 40: 131-4.
89. Gerdts B, Vloemans AF, Kreis RW. Toxic epidermal necrolysis; 15 years' experience in a Dutch burns centre. J Eur Acad Dermatol Venereol 2007; 21: 781-8.
90. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007; 56: 419-25.
91. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008; 74: 238-40.
92. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
93. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010; 85: 131-8.
94. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989-96.
95. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006; 31: 642-7.
96. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
97. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93.
98. Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004; 34: 1597-601.
99. Barranco P, Lopez-Serrano MC. General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy 1998; 28: (Suppl 4): S61-S62.
100. Haddi E, Charpin D, Tafforeau M, Kulling G, Lanteaume A, Kleisbauer JP, Vervloet D. Atopy and systemic reactions to drugs. Allergy 1990; 45: 236-9.
101. Leong KP, Thong BY, Cheng YK, Tang CY, Chng HH. Are there differences in drug allergy between the sexes? Ann Acad Med Singapore 2003; 32: 151.
102. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001; 1: 305-10.
103. Chng HH, Leong KP, Cheng YK, Tang CY, Chia FL, Tan JW, Thong BY. Elderly inpatients have drug allergy manifestations and outcome similar to the non-elderly but serious reactions are less common: results of a 9-year prospective study. Allergy 2008; 63: (Suppl 88): 379.
104. Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 480-4.
105. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7: 324-30.
106. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
107. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-8.
108. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with the HLA-B*1502 allele in a Thai population. Epilepsia 2008; 49: 2087-91.
109. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579-82.
110. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R, JSAR research group. HLA -B locus in Japaneses patients treated with antiepileptic or antimicrobial agents. Pharmacogenomics 2008; 9: 1617-22.
111. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC, RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-8.
112. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
113. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-9.
114. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
115. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2.
116. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-11.
117. Sun HY, Hung CC, Lin PH, Chang SF, Yang CY, Chang SY, Chang SC. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007; 60: 599-604.
118. Park WB, Choe PG, Song KH, Lee S, Jang HC, Jeon JH, Park SW, Park MH, Oh MD, Choe KW. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009; 48: 365-7.
119. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
120. Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci 2009; 46: 153-65.
121. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. CMAJ 2010; 182: 476-80.
122. Qiao HL, Yang J, Zhang YW. Specific serum IgE levels and FcepsilonRIbeta genetic polymorphism in patients with penicillin allergy. Allergy 2004; 59: 1326-32.
123. Qiao HL, Yang J, Zhang YW. Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillin allergy. Allergy 2005; 60: 1053-9.
124. Huang CZ, Yang J, Qiao HL, Jia LJ. Polymorphisms and haplotype analysis of IL-4Ralpha Q576R and I75V in patients with penicillin allergy. Eur J Clin Pharmacol 2009; 65: 895-902.
125. Guéant-Rodriguez RM, Romano A, Béri-Dexheimer M, Viola M, Gaeta F, Guéant JL. Gene-gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics. Pharmacogenet Genomics 2006; 16: 713-9.
126. Guglielmi L, Fontaine C, Gougat C, Avinens O, Eliaou JF, Guglielmi P, Demoly P. IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women. Allergy 2006; 61: 921-7.
127. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-30.
128. Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, Song J, Kim SH, Park HS, Min KU, Jee YK. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10: 1767-79.
129. Leiro V, Fernandez-Villar A, Valverde D, Constenla L, Vazquez R, Pineiro L, Gonzalez-Quintela A. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28: 835-9.
130. Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010; 10: 280-90.